ArticleBlood advances2018
p53 regulates CD46 expression and measles virus infection in myeloma cells.
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A three-gene radioresistance signature predicts tumor progression in cervical cancer.Translational cancer research · 2026Article
- A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity.Molecular therapy. Oncology · 2026Article
- Case Report: Unveiling the role of genetic abnormalities in myelomatous pleural effusion: a case of IgG lambda-type multiple myeloma.Frontiers in oncology · 2025Article
- Measles Virus-Based Genetic Modifications: Progress in Hematological Malignancy Treatment.OncoTargets and therapy · 2025Review
- Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.HemaSphere · 2024Article
- Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients.Frontiers in immunology · 2024Review
- Adoptive Immunotherapy and High-Risk Myeloma.Cancers · 2023Review
- Article
- Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Review
- Measles Virus as an Oncolytic Immunotherapy.Cancers · 2021Review
- MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.PLoS pathogens · 2021Article
- Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.Cancer gene therapy · 2020Article
- CD46 and Oncologic Interactions: Friendly Fire against Cancer.Antibodies (Basel, Switzerland) · 2020Review
- Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers.Molecular therapy oncolytics · 2020Article
- Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy.International journal of molecular sciences · 2020Review
- Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy.Journal of hematology & oncology · 2020Article
- Targeting Oxidative Stress With Auranofin or Prima-1Frontiers in oncology · 2019Article
- Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.Journal of hematology & oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we assessed the sensitivity of myeloma cells to the oncolytic measles virus (MV) in relation to p53 using 37 cell lines and 23 primary samples. We showed that infection and cell death were correlated with CD46 expression, which was associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.